Professor Jorge Cortes (Georgia Cancer Center, Augusta, GA, USA) summarizes two more important abstracts from the 27th Congress of the European Hematology Association (EHA) looking at magrolimab, an antibody blocking CD47, “don’t eat me” signal on cancer cells. The first is a phase III trial (NCT05079230) assessing magrolimab in combination with venetoclax and azacitidine in patients with acute myeloid leukaemia. The second is a phase 1 clinical trial (NCT03248479) looking at the impact of magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndrome.
Abstract P550: ‘A PHASE 3, RANDOMIZED TRIAL OF MAGROLIMAB IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE CHEMOTHERAPY (ENHANCE-3)’ (00:10-02:05)
Abstract P740: ‘IMPACT OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE ON RED BLOOD CELLS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS)’ (02:05-02:58)
Disclosures: Jorge Cortes is consultant for, and has received grant/research support from Novartis, Pfizer, Takeda and Sun Pharma. He is also on the Advisory Board for Novartis and Pfizer.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 27th Congress of the European Hematology Association (EHA).
